Background Data are conflicting regarding the possible effects of statins in patients with idiopathic pulmonary fibrosis (IPF). This post hoc analysis assessed the effects of statin therapy on disease-related outcomes in IPF.
Methods Patients randomised to placebo (n=624) in three controlled trials of pirfenidone in IPF (CAPACITY 004 and 006, ASCEND) were categorised by baseline statin use. Outcomes assessed during the 1-year follow-up included disease progression, mortality, hospitalisation and composite outcomes of death or ≥10% absolute decline in FVC and death or ≥50 m decline in 6-minute walk distance (6MWD).
Results At baseline, 276 (44%) patients were statin users versus 348 (56%) non-users. Baseline characteristics were similar between groups, except statin users were older and had higher prevalence of cardiovascular disease and risk factors. In multivariate analyses adjusting for differences in baseline characteristics, statin users had lower risks of death or 6MWD decline (HR 0.69; 95% CI 0.48 to 0.99, p=0.0465), all-cause hospitalisation (HR 0.58; 95% CI 0.35 to 0.94, p=0.0289), respiratory-related hospitalisation (HR 0.44; 95% CI 0.25 to 0.80, p=0.0063) and IPF-related mortality (HR 0.36; 95% CI 0.14 to 0.95, p=0.0393) versus non-users. Non-significant treatment effects favouring statin use were observed for disease progression (HR 0.75; 95% CI 0.52 to 1.07, p=0.1135), all-cause mortality (HR 0.54; 95% CI 0.24 to 1.21, p=0.1369) and death or FVC decline (HR 0.71; 95% CI 0.48 to 1.07, p=0.1032).
Conclusions This post hoc analysis supports the hypothesis that statins may have a beneficial effect on clinical outcomes in IPF. Prospective clinical trials are required to validate these observations.
- Idiopathic pulmonary fibrosis
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
What is the key question?
Do statins have an effect on disease-related outcomes in patients with idiopathic pulmonary fibrosis (IPF)?
What is the bottom line?
In a large and well defined cohort of patients with IPF, statins were associated with reductions in IPF-related mortality, hospitalisation and disease progression compared with patients who did not receive statins.
Why read on?
Statins are frequently prescribed for concomitant cardiovascular disease and risk factors in patients with IPF, and have previously been linked with both detrimental and beneficial actions on IPF progression.
Idiopathic pulmonary fibrosis (IPF) is a serious, debilitating and progressive lung disease that presents with exertional dyspnoea and cough.1–3 IPF is diagnosed more frequently among men than women, during the seventh or eighth decade of life and among current or ex-smokers.4 IPF is associated with substantial healthcare requirements and patients with IPF typically require frequent hospitalisations as a consequence of their disease.5 Furthermore, the prognosis for patients with IPF is poor and survival rates are lower than those reported for many common cancers.6 ,7 The 5-year survival rate for patients from the time of diagnosis is between 20% and 40%,8 with a median survival of between 2 years and 5 years.2 ,7
Two antifibrotic drugs are approved for the treatment of IPF, pirfenidone9 ,10 and nintedanib.11 Both drugs have been shown to significantly reduce the decline in FVC compared with placebo among patients with IPF.9–11 Pirfenidone has also been shown to improve survival among patients with IPF: a pooled analysis of data found a 48% reduction in mortality compared with placebo after 1 year of treatment with pirfenidone (p=0.01).9
Cardiovascular (CV) comorbidities are common in IPF12 and medications are often required to treat patients with CV risk factors. This includes the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor or ‘statin’ class of drugs, which are widely used for their cholesterol-lowering effects and associated reduction in the risk for CV morbidity.13 ,14 The potential for additional benefits from statin therapy has been investigated previously. For example, statins have been shown to attenuate the decline in pulmonary function associated with normal ageing, with the magnitude of the protective effect apparently modified by smoking status.15 Furthermore, the effect of statins on disease-related outcomes in patients with COPD has also been investigated.16 However, the relationship between statins and the development of interstitial lung disease (ILD) is controversial. Case reports and, most recently, a regression analysis of current and former smokers included in the COPDGene study suggest that statin use may be associated with the presence of interstitial lung abnormalities, at least among patients who are current or ex-smokers.17 ,18
In contrast, a recent analysis of a health administrative database that included 6665 individuals with possible or probable ILD and 26 660 matched control subjects, did not reveal an association between statin use and the incidence of ILD.19 Conflicting data have also emerged with regard to the effect of statins in patients with established lung disease such as IPF. Animal studies have shown that statins prevent the development of pulmonary fibrosis, although they do not appear to attenuate established pulmonary fibrosis.20 In a small retrospective analysis of data from 35 patients with IPF, no association between statin therapy and mortality was identified.21 However, a more recent analysis of data from the national Danish Patients Registry found that statin use was associated with reduced mortality among patients with ILD, including those with IPF.22
To further investigate the potential effects of statins in patients with IPF, a post hoc analysis was performed using data from the placebo arms of the pirfenidone phase III programme. The effect of statins on mortality and other clinically relevant disease-related outcomes was investigated in this well defined population of patients with IPF.
Materials and methods
This was a post hoc analysis of data from the placebo arms of three phase III, randomised, controlled, double-blind clinical trials of pirfenidone in IPF: Study 016, Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND; NCT01366209);9 and Study 004 and Study 006, Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis (CAPACITY; NCT00287729 and NCT00287716, respectively).10 Patient enrolment took place from July 2011 to January 2013, and from April 2006 to November 2008 in the ASCEND and CAPACITY trials, respectively. ASCEND and CAPACITY were conducted in accordance with the International Conference on Harmonisation Guidelines and the Declaration of Helsinki, as well as the relevant local legal and regulatory requirements of the countries in which the trials were conducted. Written informed consent was obtained from all patients prior to any study procedure.
ASCEND and CAPACITY recruited patients aged between 40 years and 80 years who had a confirmed diagnosis of IPF by high-resolution CT (HRCT) alone or HRCT plus surgical lung biopsy. Eligible patients had an FVC ≥50% (and ≤90% in the ASCEND trial), per cent predicted carbon monoxide diffusing capacity ≥35% (≥30% and ≤90% in the ASCEND trial) and a 6-minute walk distance (6MWD) ≥150 m with no evidence of improvement in measures of IPF disease severity over the preceding year. Patients showing significant clinical worsening of IPF as judged by the investigator, or a difference in FVC >10% between screening and day 1, were excluded. Other exclusion criteria were clinically significant concomitant disease including a history of unstable or deteriorating cardiac disease within the previous 6 months, and active infection or malignancy. Patients with a history of COPD were excluded from ASCEND, but were eligible for the CAPACITY studies if the condition had not led to hospitalisation within 6 months prior to study entry.9 ,10 The use of concomitant medication, including statins, was ascertained through open-ended questioning by study investigators.
The outcomes evaluated were disease progression (defined as the first occurrence of any of the following: ≥10% absolute decline in per cent predicted FVC, a decline of at least 50 m in 6MWD (both required confirmation at two consecutive assessments at least 6 weeks apart) or death), all-cause mortality, IPF-related mortality (the cause of death was assessed by blinded clinical investigators in CAPACITY and a mortality assessment committee in ASCEND), change from baseline in FVC, change from baseline in 6MWD, all-cause hospitalisation and respiratory-related hospitalisation (defined as a hospitalisation in which the primary reason for admission was determined to be respiratory related by the investigator). The composite outcomes of all-cause mortality or a ≥10% absolute decline in per cent predicted FVC and all-cause mortality or a ≥50 m decline in 6MWD were prespecified outcomes in ASCEND.9 All outcomes were evaluated over 1 year.
Demographic and clinical characteristics of the study population categorised by statin use at baseline, and corresponding crude (unadjusted) risks of binary study outcomes among statin users and non-users, were compared. Statistical comparisons were undertaken using an independent-samples t-test for continuous variables and a χ2 test for categorical variables.
A shared frailty model (an extension of the Cox proportional hazards model that adjusts for intracluster (ie, intratrial) correlation) was employed to examine the relationship between statin use and study outcomes without adjustment (bivariate model), and with adjustment for age, sex, smoking status, lung function, exercise tolerance, dyspnoea, medical history and CV risk factors (multivariate model). Survival analyses were based on the Kaplan-Meier estimator, and comparisons of statin users and non-users were based on the log-rank test. Only observed data were employed in analyses (ie, missing values were not imputed). Individuals were censored at the time of loss to follow-up, at the time of lung transplantation or at the end of the 1-year follow-up period, whichever occurred first. The presence of multicollinearity, hazards assumptions and treatment of death as a competing risk (where appropriate) were evaluated using published methods.23 ,24 SAS V.9.3 for Windows was used to evaluate the proportionality assumption for statin use using a time-dependent covariate (ie, interaction between statin and time). Models not considering death as an outcome were estimated, alternatively treating death as a competing risk rather than censoring on death.
A total of 624 patients were included in this post hoc analysis (ASCEND, n=277; CAPACITY, n=347), of whom 276 (44.2%) were receiving statin therapy at baseline (simvastatin, 38.4%; atorvastatin, 34.8%; pravastatin, 9.8%; rosuvastatin, 9.4%; other, 7.6%). The mean (SD) duration of follow-up was 348.3 (58.8) days in patients who received statins and 342.7 (67.8) days in those who did not. During the 1-year follow-up, one statin user and four statin non-users received a lung transplant.
Statin users were older than non-users and a greater proportion of statin users were male (table 1).
Baseline lung function and exercise capacity were similar between the two groups. However, those receiving statins had a significantly higher prevalence of CV disease at baseline. The prevalence of the following CV risk factors was higher among statin users than non-users: hypertension, smoking (current and former), diabetes and hypercholesterolaemia (table 1).
Results from the crude analysis and bivariate frailty model are presented in table 2.
In multivariate analyses, there was a non-significant treatment effect favouring statin use for the composite disease-progression outcome (multivariate HR 0.75; 95% CI 0.52 to 1.07, p=0.1135) (figure 1; table 3). Statin users had a significantly lower risk versus non-users for the composite outcome of all-cause mortality or a decrease of ≥50 m in 6MWD (multivariate HR 0.69; 95% CI 0.48 to 0.99, p=0.0465), all-cause hospitalisation (multivariate HR 0.58; 95% CI 0.35 to 0.94, p=0.0289), respiratory-related hospitalisation (multivariate HR 0.44; 95% CI 0.25 to 0.80, p=0.0063) and IPF-related mortality (multivariate HR 0.36; 95% CI 0.14 to 0.95, p=0.0393) (table 3). There was no significant difference between treatment groups for ≥10% absolute decline in per cent predicted FVC (multivariate HR 0.81; 95% CI 0.47 to 1.40, p=0.4533), the composite outcome of all-cause mortality or a ≥10% decline in per cent predicted FVC (multivariate HR 0.71; 95% CI 0.48 to 1.07, p=0.1032) (figure 2) and all-cause mortality (multivariate HR 0.54; 95% CI 0.24 to 1.21, p=0.1369) (table 3).
The results of this post hoc analysis of data from patients with IPF from the placebo arms of the CAPACITY and ASCEND trials provide support for the hypothesis that statin therapy may have a beneficial effect on IPF-related outcomes. In particular, statins were associated with reduced hospitalisation and mortality.
Previous studies undertaken to evaluate the potential impact of statins on outcomes in patients with IPF have provided conflicting results. A small, retrospective analysis of data from 35 patients with IPF did not show an association between statin therapy and mortality.21 However, more than half of the patients in this study received immunosuppressive therapy which has recently been associated with increased mortality in the PANTHER trial25 and which may, therefore, have confounded the results. In contrast, a more recent analysis of data from the national Danish Patients Registry found that statin use was associated with reduced mortality among 783 patients with IPF. However, the International Classification of Diseases, 10th revision coding was used in this analysis, and may have introduced bias due to poor definition of baseline lung function and other potential risk factors for adverse outcomes.22
Our analyses did not identify a beneficial interaction between statin use and current/former smoking status for any outcome contrary to previous observations reported by Alexeeff et al. Alexeeff et al15 reported a statistically significant (p<0.001) three-way interaction between time since first study visit, statin use and smoking status in elderly men enrolled in a longitudinal observational study. Their results suggested that statins might act by attenuating the negative effects of smoking on the normative decline in lung function associated with ageing. However, lung function decline in patients with IPF differs to that associated with normal ageing,8 ,26 ,27 thus complicating valid comparison between the two populations.
The pathophysiology of IPF is very complex and the mechanism by which statins may affect cellular and/or molecular pathways to reduce disease progression remains to be explained. Repetitive microscopic injury to alveolar epithelial cells type II (AECII) is thought to be an important component of the pathogenesis of IPF. AECII death and perturbation of normal epithelial homoeostasis may result in uncontrolled repair mechanisms, resulting in fibroblast proliferation and activation and, ultimately, lung fibrosis.28 ,29 Multiple pathways are involved both in AECII death and in lung fibrosis, and the relative contribution of these pathways in the development of IPF is currently an important knowledge gap. In vitro studies have long suggested a modulatory effect of statins on pathways of fibrosis in humans.30 ,31 In experiments using a human renal fibroblast cell line (TK173), exposure to statins resulted in a reversible and time-dependent change in cell morphology, including the actin skeleton, with concomitant changes in the basal expression of the profibrotic protein connective tissue growth factor.30 This finding was reproduced in an in vitro study that found a reduction in the expression of the profibrotic connective tissue growth factor in lung fibroblasts treated with statins.32 Perhaps more indirectly, statins have been shown to reduce the expression of the glycoprotein thrombospondin-1 by human vascular smooth muscle cells;31 thrombospondin-1 is a known activator of transforming growth factor-β (TGF-β), a key profibrotic protein implicated in fibrogenesis.33
Pathophysiological processes other than those related directly to fibrosis may also underpin a beneficial effect of statins in patients with IPF. Statins are known to exert an anti-inflammatory effect and it is possible that this action may explain the apparent protective effect of these agents in patients with IPF. In a rat model, statins appeared to be protective against smoking-induced lung damage through anti-inflammatory effects in the lung itself, particularly inhibition of inflammatory cell infiltration.34 Consistent with this latter observation, statin use was associated with reduced levels of neutrophils and lymphocytes in the bronchoalveolar lavage fluid of patients after lung transplantation with a variety of underlying diagnoses including emphysema, cystic fibrosis and IPF. The 6-year survival of patients with lung transplant who received statins was also significantly greater than that of patients who did not receive statins (91% vs 54%; p<0.01).35 Furthermore, statins have been shown to suppress the production of TGF-β and the inflammatory chemokine, interleukin (IL) 8, in human lung tissue.36–38 However, this is in contrast to an in vitro study which found that statins increased mitogen-activated peripheral blood monocyte secretion of IL-18 and IL-1β,39 two cytokines that have been implicated in bleomycin-induced lung injury.40
Our analysis was the first evaluation of statin use in a large, well defined cohort of patients with IPF with regular follow-up. In contrast to earlier evidence which had suggested a link between statin use and the development of interstitial lung abnormalities17 ,18 our results add weight to the hypothesis that statins may exert a beneficial effect in patients with IPF. However, the conclusions that can be drawn are limited by the post hoc nature of the analysis. Statin therapy may address an increased risk of all-cause death or hospitalisation as a result of comorbid conditions. Yet a comparison of the baseline characteristics of the patients in the two groups suggested that those receiving statins had higher CV risk than those not receiving statins, as might be expected given the CV-related indications for statin therapy. Additionally, our analyses have suggested a potentially more specific effect of statins on IPF-related mortality and respiratory-related hospitalisations, which might not be anticipated if the impact of statins was related only to CV comorbidities.
Furthermore, our results are limited to patients with IPF who are not treated with antifibrotics. Future studies of statins in IPF are likely to include patients receiving antifibrotics, therefore a post hoc analysis designed to investigate the effect of pirfenidone and statins in combination is planned, using data from the pirfenidone arms of the ASCEND and CAPACITY studies.
In conclusion, the results presented here provide support for the hypothesis that statins may be beneficial in patients with IPF. Future studies should include prospective analyses of statin use in IPF and their potential use in combination with antifibrotic therapies.
Contributors MKr, MKo and DW were involved in the design of the analysis. DW was involved in the execution of the analysis. All authors were involved in the interpretation of the results. All authors were involved in drafting and revising this manuscript, and provided final approval of the version to be published. All authors vouch for the accuracy of the content included in the final manuscript.
Funding The sponsor, F. Hoffmann-La Roche, funded the analysis of the data by Policy Analysis Inc. (PAI). Programming support was provided by Mark Atwood of Policy Analysis Inc. (PAI). Medical writing support was provided by Dr Tracey Lonergan on behalf of Complete Medical Communications Ltd, funded by F. Hoffmann-La Roche Ltd.
Competing interests MKr and his institution have received unrestricted grants and personal fees from InterMune International AG which became a wholly owned subsidiary of Roche in 2014, F. Hoffmann-La Roche Ltd and Boehringer Ingelheim. FB has received speaker fees, advisory board honoraria or grants from InterMune International AG which became a wholly owned subsidiary of Roche in 2014, Boehringer Ingelheim, Gilead, Serendex, Centocor and F. Hoffmann-La Roche Ltd. TMM is supported by a National Institute for Health Research Clinician Scientist Fellowship (NIHR Ref: CS:-2013-13-017). He has received research grants from GlaxoSmithKline, UCB and Novartis; and consulting and speaker fees from AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, Dosa, GlaxoSmithKline, Lanthio, InterMune International AG which became a wholly owned subsidiary of Roche in 2014, F. Hoffmann-La Roche Ltd, Sanofi-Aventis, Takeda and UCB. UC has received grants, personal fees and non-financial support from Boehringer Ingelheim. He has received grants, personal fees and non-financial support from Intermune International AG which became a wholly owned subsidiary of Roche in 2014, and personal fees from F. Hoffmann-La Roche Ltd, Bayer, Gilead, GlaxoSmithKline, UCB, Biogen and Centocor (all outside the submitted work). PS has received consulting fees from InterMune International AG which became a wholly owned subsidiary of Roche in 2014, F. Hoffmann-La Roche Ltd and Santhera Pharmaceuticals Ltd, and personal fees from Boehringer Ingelheim and Novartis. DW is an employee of Policy Analysis Inc. (PAI), which received funding from F. Hoffmann-La Roche Ltd for this study. K-UK is an employee of F. Hoffmann-La Roche Ltd, Basel, Switzerland. MKo has served as site Principal Investigator in industry-sponsored clinical trials (Centocor, Roche, Sanofi and Boehringer Ingelheim) and is funded by the Canadian Institute for Health Research. He has served and/or serves on the Pulmonary Fibrosis Foundation Medical Advisory Board and on Advisory Boards for Boehringer Ingelheim, Roche Canada, GlaxoSmithKline, AstraZeneca, Vertex, Genoa, Gilead, Janssen and Prometic.
Ethics approval Ethics committee/institutional review board approval was obtained from each centre participating in the ASCEND and CAPACITY studies (total of 237 centres) as presented in the primary papers reporting the results of those trials (King et al,9 and Noble et al,10). A full list can be provided if required.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.